InnerCool enters Europe via Euromed
This article was originally published in Clinica
Executive Summary
Temperature modulation specialist InnerCool Therapies has enlisted cardiology products distributor Euromed Medizinisch to make its technology available in Europe for the first time. The exclusive deal, of which financial details were not disclosed, will see Vienna, Austria-based Euromed distribute the CoolBlue surface cooling temperature modulation system and the RapidBlue endovascular cooling system in Austria, Germany and Switzerland. The CoolBlue product was launched in the US during Q4 2007 and is expected to go on sale through Euromed this quarter. The RapidBlue device is set to go to the US market during the second quarter of 2008 and become commercially available third quarter. The deal with Euromed follows InnerCool's recent distribution deal with Lifehealthcare for the Australian and New Zealand markets. A spokesperson for InnerCool told Clinica that the company would be entering into further deals to strengthen its presence outside the US. San Diego, California-based InnerCool is a subsidiary of interventional cardiology specialist Cardium Therapeutics.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.